Ultragenyx Pharmaceutical Inc.
RARENASDAQHealthcare● Active
$21.59
$-0.32(-1.46%)
Market Cap$2.1B
P/E Ratio—
52W High$42.37
52W Low$18.29
Ultragenyx Pharmaceutical Inc. (RARE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RARE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$1.84
Est. -$1.49 · -23.7%
Revenue
$0.14B
Est. $0.16B · -14.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
RARE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$1.24 | — | — | — | $0.18B | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$1.49 | -$1.84 | -23.7% | $0.14B | $0.16B | -14.0% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -$1.20 | -$1.29 | -7.5% | $0.21B | $0.20B | +4.2% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$1.23 | -$1.81 | -47.1% | $0.16B | $0.20B | -19.9% |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$1.27 | -$1.17 | +7.9% | $0.17B | $0.17B | +0.3% |
| ▼ Q2 FY2025 | May 6, 2025 | -$1.54 | -$1.57 | -1.9% | $0.14B | $0.16B | -14.2% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -$1.32 | -$1.39 | -5.3% | $0.16B | $0.16B | +3.9% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$1.45 | -$1.40 | +3.5% | $0.14B | $0.15B | -4.8% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$1.24
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$1.84
EPS Est.
-$1.49
EPS Surpr.
-23.7%
Revenue
$0.14B
Q1 FY2026
Feb 12, 2026Miss
EPS Actual
-$1.29
EPS Est.
-$1.20
EPS Surpr.
-7.5%
Revenue
$0.21B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$1.81
EPS Est.
-$1.23
EPS Surpr.
-47.1%
Revenue
$0.16B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$1.17
EPS Est.
-$1.27
EPS Surpr.
+7.9%
Revenue
$0.17B
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$1.57
EPS Est.
-$1.54
EPS Surpr.
-1.9%
Revenue
$0.14B
Q1 FY2025
Feb 13, 2025Miss
EPS Actual
-$1.39
EPS Est.
-$1.32
EPS Surpr.
-5.3%
Revenue
$0.16B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$1.40
EPS Est.
-$1.45
EPS Surpr.
+3.5%
Revenue
$0.14B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.50 | $0.62 | $0.70 | 1 |
| Q3 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2027 | $-0.25 | $-0.23 | $-0.18 | 1 |
| Q1 FY2027 | $-0.79 | $-0.71 | $-0.56 | 1 |
| Q4 FY2026 | $-0.53 | $-0.47 | $-0.37 | 1 |
| Q3 FY2026 | $-1.49 | $-1.03 | $0.28 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.3B | $0.3B | $0.4B | 5 |
| Q3 FY2027 | $0.2B | $0.3B | $0.3B | 5 |
| Q2 FY2027 | $0.2B | $0.2B | $0.3B | 5 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 5 |
| Q4 FY2026 | $0.2B | $0.2B | $0.3B | 5 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 10 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -23.7% | $24.81 | $25.01 | +0.81% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -7.5% | $23.88 | $23.50 | -1.59% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -47.1% | $33.47 | $32.46 | -3.02% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +7.9% | $28.46 | $28.92 | +1.62% |
| ▼ Q2 FY2025 | May 6, 2025 | -1.9% | $38.87 | $35.06 | -9.80% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -5.3% | $43.43 | $43.52 | +0.21% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +3.5% | $51.06 | $52.18 | +2.19% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +7.3% | $45.02 | $44.15 | -1.93% |
Q2 FY2026+0.81%
Report Date
May 5, 2026
EPS Beat/Miss
-23.7%
Price Before
$24.81
Price After
$25.01
Q1 FY2026-1.59%
Report Date
Feb 12, 2026
EPS Beat/Miss
-7.5%
Price Before
$23.88
Price After
$23.50
Q4 FY2025-3.02%
Report Date
Nov 4, 2025
EPS Beat/Miss
-47.1%
Price Before
$33.47
Price After
$32.46
Q3 FY2025+1.62%
Report Date
Aug 5, 2025
EPS Beat/Miss
+7.9%
Price Before
$28.46
Price After
$28.92
Q2 FY2025-9.80%
Report Date
May 6, 2025
EPS Beat/Miss
-1.9%
Price Before
$38.87
Price After
$35.06
Q1 FY2025+0.21%
Report Date
Feb 13, 2025
EPS Beat/Miss
-5.3%
Price Before
$43.43
Price After
$43.52
Q4 FY2024+2.19%
Report Date
Nov 5, 2024
EPS Beat/Miss
+3.5%
Price Before
$51.06
Price After
$52.18
Q3 FY2024-1.93%
Report Date
Aug 1, 2024
EPS Beat/Miss
+7.3%
Price Before
$45.02
Price After
$44.15
Avg Beat Reaction+0.63%
Avg Miss Reaction-2.68%
Beat Rate3 / 8 quarters
Largest Move-9.80% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RARE ends December
Ultragenyx Pharmaceutical Inc. (RARE) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-1.84 — missing the analyst consensus of $-1.49 by -23.7%. The next RARE earnings date is expected around September 1, 2026.
Each quarter, investors track RARE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RARE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RARE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RARE earnings · 5 questionsUltragenyx Pharmaceutical Inc.'s next earnings report is expected around September 1, 2026. RARE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RARE historically reports after market close (AMC).
RARE earnings datewhen is RARE earningsRARE next earnings datewhen does RARE report earningsRARE earnings calendar
▸ Source: FMP · Ultragenyx Pharmaceutical Inc. SEC filings · US GAAP · Ultragenyx Pharmaceutical Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026